Business Context and Reporting Period
This Form 8-K is a current report filed by Synta Pharmaceuticals Corp. on August 19, 2011. The filing addresses the entry into a material definitive agreement regarding an existing equity line of credit arrangement. Note: The request metadata references "MADRIGAL PHARMACEUTICALS, INC.", but the filing text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on a corporate transaction.
- Equity Line Capacity: Up to $35,000,000 or 8,106,329 shares of common stock (whichever is lesser).
- Counterparty: Azimuth Opportunity Ltd.
- Registration Status: Shares are now registered under a new Form S-3 (File No. 333-176022), declared effective August 19, 2011.
Material Changes
The primary material change is the amendment to the Common Stock Purchase Agreement originally dated October 4, 2010.
- Registration Update: The shares to be sold under the agreement were previously registered on a Form S-3 (File No. 333-152833) that was set to expire on August 28, 2011.
- Amendment Execution: On August 19, 2011, the Company and Azimuth executed an amendment to reflect the new registration statement.
- Termination: The prior registration statement was terminated immediately following the effectiveness of the new statement.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies beyond the standard legal qualification that the summary is subject to the full terms of the Amendment filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the terms of the Amendment No. 1 filed as Exhibit 10.1 to ensure no other terms of the Purchase Agreement were altered.
- Confirm the status of the new Form S-3 (File No. 333-176022) and its effective date.
- Review the Company's subsequent filings to determine if any shares have been sold under this amended agreement.
- Clarify the discrepancy between the request metadata (Madrigal Pharmaceuticals) and the filing registrant (Synta Pharmaceuticals).